Advertisement

EPMA Journal

pp 1–14 | Cite as

Current approaches in the clinical management of pregnancy-associated breast cancer—pros and cons

  • Pavol Zubor
  • Peter Kubatka
  • Ivana Kapustova
  • Lence Miloseva
  • Zuzana Dankova
  • Alexandra Gondova
  • Tibor Bielik
  • Stefan Krivus
  • Jan Bujnak
  • Zuzana Laucekova
  • Christina Kehrer
  • Erik Kudela
  • Jan Danko
Review
  • 22 Downloads

Abstract

Malignancies are one of the leading causes of mortality in women during their reproductive life. Treatment of gynecological malignant tumors during pregnancy is possible but not simple, since it creates a conflict between care of the mother and the fetus. BC is the most prevalent malignancy diagnosed in pregnancy, ranking up to 21% of all pregnancy-related malignancies. Due to its stets increasing prevalence, aggressive cancer subtype, and severe ethical and psychological aspects linked to the disease, experts raise an alarm for an acute necessity to improve the overall management of the PABC—the issue which has strongly motivated our current paper. Comprehensive research data and clinical experience accumulated in recent years have advanced our understanding of the disease complexity. PABC treatment must be individualized with an emphasis on optimal care of the mother, while observing standard treatment protocols with regard to safety of the fetus. Treatment protocols should be elaborated based on the individualized patient profile, bearing in mind the acute danger to the mother, maximizing the therapy efficacy and minimizing harmful effects to the fetus. Complex consulting on treatment options, their impacts on pregnancy and potential teratogenic effects requires tight “doctor-patient” collaboration. Complications that may arise due to the treatment of breast cancer in pregnancy require a multiprofessional expertise including oncologists, neonatologists, perinatologists, obstetricians, teratologists, and toxicologists, and an extensive psychological support throughout the pregnancy and after giving birth. Thereby, specifically psychological aspects of PABC diagnosis and follow-up are frequently neglected, being not yet adequately explored in the entire disease management approach. Herewith, we update the status quo regarding the currently available diagnostic modalities, complex treatment algorithms, and novel clinical approaches which altogether argue for an urgent necessity of a paradigm shift moving away from reactive to predictive, preventive, and personalized medical approach in the overall management of PABC meeting the needs of young populations, persons at high risk, affected patients, and families as the society at large.

Keywords

Pregnancy Breast cancer Diagnostics Treatment Chemotherapy Radiotherapy Psychological aspects Preventive predictive personalized medicine 

Notes

Acknowledgements

This work has been supported by the following organizations: European Association for Predictive, Preventive, and Personalized Medicine, EPMA, Brussels, Belgium; Slovak Research and Development Agency (under contract no. APVV-16-0021), the Scientific Grant Agency, Ministry of Education, Science, and Research, Slovak Republic; and the VEGA Grant Agency (1/0124/17), Ministry of Education, Science and Research, Slovak Republic

Compliance with ethical standards

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of informed consent

Patients have not been involved in the study.

Statement of human and animal rights

No experiments have been performed including patients and/or animals.

References

  1. 1.
    Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, et al. Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. 2016;37(10):12941–57.CrossRefGoogle Scholar
  2. 2.
    Triunfo S, Scambia G. Cancer in pregnancy: diagnosis, treatment and neonatal outcome. Minerva Ginecol. 2014;66(3):325–34.PubMedGoogle Scholar
  3. 3.
    Lee YY, Roberts CL, Dobbins T, Stavrou E, Black K, Morris J, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. BJOG. 2012;119(13):1572–82.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Polivka J, Altun I, Golubnitschaja O. Pregnancy-associated breast cancer: the risky status quo and new concepts of predictive medicine. EPMA J. 2018;9(1):1–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Dickman PW, Lambe M. Family history and risk of pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat. 2015;151(1):209–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Keyser EA, Staat BC, Fausett MB, Shields AD. Pregnancy-associated breast Cancer. Rev Obstet Gynec. 2012;5(2):94–9.Google Scholar
  7. 7.
    McGrath SE, Ring A. Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists. Ther Adv Med Oncol. 2011;3(2):73–83.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vinatier E, Merlot B, Poncelet E, Collinet P, Vinatier D. Breast Cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):9–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Gupta PB, Kuperwasser CJ. Contributions of estrogen to ER-negative breast tumor growth. Steroid Biochem Mol Biol. 2006;102(1–5):71–8.CrossRefGoogle Scholar
  10. 10.
    John EM, Hines LM, Phipps AI, Koo J, Longacre TA, Ingles SA, et al. Reproductive history, breast-feeding and risk of triple negative breast cancer: the breast Cancer etiology in minorities (BEM) study. Int J Cancer. 2018;142(11):2273–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat Rev. 2010;36(2):110–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Muñoz-Rodríguez JL, Vrba L, Futscher BW, Hu C, Komenaka IK, Meza-Montenegro MM, et al. Differentially expressed microRNAs in postpartum breast cancer in Hispanic women. PLoS One. 2015;10(4):e0124340.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Golubnitschaja O, Costigliola V, Grech G. EPMA World Congress: traditional forum in predictive, preventive and personalised medicine for multi-professional consideration and consolidation. EPMA J. 2017;8(Suppl):1–54.Google Scholar
  15. 15.
    Yu HH, Cheung PS, Leung RC, Leung TN, Kwan WH. Current management of pregnancy-associated breast cancer. Hong Kong Med J. 2017;23(4):387–94.PubMedGoogle Scholar
  16. 16.
    Ahn BY, Kim HH, Moon WK, Pisano ED, Kim HS, Cha ES, et al. Pregnancy- and-lactation-associated breast cancer: mammographic and sonographic findings. J Ultrasound Med. 2003;22(5):491–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? J Clin Oncol. 2013;31(20):2521.CrossRefPubMedGoogle Scholar
  18. 18.
    Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Women's Health (Lond Engl). 2009;5(3):243–9.CrossRefGoogle Scholar
  19. 19.
    Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG Jr, Froelich JW, et al. ACR blue ribbon panel on MR safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188(6):1447–74.CrossRefPubMedGoogle Scholar
  20. 20.
    Sundgren PC, Leander P. Is administration of gadolinium-based contrast media to pregnant women and small children justified? J Magn Reson Imaging. 2011;34(4):750–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Heymann JJ, Halligan AM, Hoda SA, Facey KE, Hoda RS. Fine needle aspiration of breast masses in pregnant and lactating women: experience with 28 cases emphasizing Thinprep findings. Diagn Cytopathol. 2015;43(3):188–94.CrossRefPubMedGoogle Scholar
  22. 22.
    Mitra S, Dey P. Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: a comparison and review of the literature. Cytojournal. 2016;13:18.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nettleton J, Long J, Kuban D, Wu R, Shaefffer J, El-Mahdi A. Breast cancer during pregnancy: quantifying the risk of treatment delay. Obstet Gynecol. 1996;87(3):414–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Szecsi PB, Andersen MR, Bjørngaard B, Hedengran KK, Stender S. Cancer antigen 125 after delivery in women with normal pregnancy: a prospective cohort study. Acta Obstet Gynecol Scand. 2014;93(12):1295–301.CrossRefPubMedGoogle Scholar
  25. 25.
    Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012;8(10):86.CrossRefGoogle Scholar
  26. 26.
    Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206(4):349.e1–7.CrossRefGoogle Scholar
  27. 27.
    Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–41.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Jayasinghe Y. Preventive care and evaluation of the adolescent with a breast mass. Semin Plast Surg. 2013;27(1):13–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Bick U. Intensified surveillance for early detection of breast cancer in high-risk patients. Breast Care (Basel). 2015;10(1):13–20.CrossRefGoogle Scholar
  30. 30.
    Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102(10):680–91.CrossRefPubMedGoogle Scholar
  31. 31.
    Corsini C, Henouda S, Nejima DB, Bertet H, Toledano A, Boussen H, et al. Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between north African and south European women. Breast Cancer Res Treat. 2017;166(2):631–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Zubor P, Gondova A, Polivka J, Kasajova P, Konieczka K, Danko J, et al. Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach? EPMA J. 2017;8(2):129–40.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Bubnov R, Polivka J, Zubor P, Konieczka K, Golubnitschaja O. “Pre-metastatic niches” in breast cancer: are they created by or prior to the tumour onset? “Flammer syndrome” relevance to address the question. EPMA J. 2017;8(2):141–57.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Smokovski I, Risteski M, Polivka J, Zubor P, Konieczka K, Costigliola V, et al. Postmenopausal breast cancer: European challenge and innovative concepts. EPMA J. 2017;8(2):159–69.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Per Med. 2016;13:469–84.CrossRefPubMedGoogle Scholar
  37. 37.
    Maltoni R, Fici P, Amadori D, Gallerani G, Cocchi C, Zoli M, et al. Circulating tumor cells in early breast cancer: a connection with vascular invasion. Cancer Lett. 2015;367(1):43–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Novel strategies on personalized medicine for breast Cancer treatment: an update. Int J Mol Sci. 2017;18(11):E2423.CrossRefPubMedGoogle Scholar
  39. 39.
    Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6(1):9.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283–91.CrossRefPubMedGoogle Scholar
  41. 41.
    Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6(6):821–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Ji YI, Kim KT. Gynecologic malignancy in pregnancy. Obstet Gynecol Sci. 2013;56(5):289–300.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Moran BJ, Yano H, Al Zahir N, Farquharson M. Conflicting priorities in surgical intervention for cancer in pregnancy. Lancet Oncol. 2007;8(6):536–44.CrossRefPubMedGoogle Scholar
  44. 44.
    Gentilini O, Cremonesi M, Toesca A, Colombo N, Peccatori F, Sironi R, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37(1):78–83.CrossRefPubMedGoogle Scholar
  45. 45.
    Kuerer HM, Gwyn K, Ames FC, Theriault RL. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery. 2002;131(1):108–10.CrossRefPubMedGoogle Scholar
  46. 46.
    Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, et al. Wound complications from surgery in pregnancy- associated breast cancer (PABC). Breast Dis. 2010;31(1):1–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Khera SY, Kiluk JV, Hasson DM, Meade TL, Meyers MP, Dupont EL, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14(3):250–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Amant F, Halaska MJ, Fumagalli M, Dahl Steffensen K, Lok C, Van Calsteren K, et al. ESGO task force ‘Cancer in pregnancy’. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014;24(3):394–403.CrossRefPubMedGoogle Scholar
  49. 49.
    Greskovich JF Jr, Macklis RM. Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol. 2000;27(6):633–45.PubMedGoogle Scholar
  50. 50.
    Rovera F, Chiappa C, Coglitore A, Baratelli GM, Fachinetti A, Marelli M, et al. Management of breast cancer during pregnancy. Int J Surg. 2013;11(Suppl 1):S64–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010;46(18):3158–68.CrossRefPubMedGoogle Scholar
  52. 52.
    Cardonick E. Pregnancy-associated breast cancer: optimal treatment options. Int J Womens Health. 2014;6:935–43.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006;65(5):1353–60.CrossRefPubMedGoogle Scholar
  54. 54.
    Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008;87(1):3–16.CrossRefPubMedGoogle Scholar
  55. 55.
    Espie M, Cuvier C. Treating breast cancer during pregnancy – what can be taken safely. Drug Saf. 1998;2(18):135–42.CrossRefGoogle Scholar
  56. 56.
    Han SN, Van Calsteren K, Heyns L, Mhallem Gziri M, Amant F. Breast cancer during pregnancy: a literature review. Minerva Ginecol. 2010;62(6):585–97.PubMedGoogle Scholar
  57. 57.
    Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44(3):428–30.CrossRefPubMedGoogle Scholar
  58. 58.
    Padmagirison R, Gajjar K, Spencer C. Management of breast cancer during pregnancy. Obstet Gynaecol. 2010;12:186–92.Google Scholar
  59. 59.
    de Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19(3):337–46.CrossRefPubMedGoogle Scholar
  60. 60.
    Azim HA Jr, Del Mastro L, Scargone G, Peccatori FA. Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more…. Breast. 2011;20(1):1–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Krishna I, Lindsay M. Breast cancer in pregnancy. Obstet Gynecol Clin North Am. 2013;40(3):559–71.CrossRefPubMedGoogle Scholar
  62. 62.
    Framarino-Dei-Malatesta M, Sammartino P, Napoli A. Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus? BMC Cancer. 2017;17(1):777.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Mir O, Berveiller P. Increased evidence for use of chemotherapy in pregnancy. Lancet Oncol. 2012;13(9):852–4.CrossRefPubMedGoogle Scholar
  64. 64.
    Zagouri F, Sergentanis TN, Chrysikos D, Dimitrakakis C, Tsigginou A, Zografos CG, et al. Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer. 2013;13(1):16–23.CrossRefPubMedGoogle Scholar
  65. 65.
    Zagouri F, Dimitrakakis C, Marinopoulos S, Tsigginou A, Dimopoulos MA. Cancer in pregnancy: disentangling treatment modalities. ESMO Open. 2016;1(3):e000016.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Negro A, Brar BK, Gu Y, Peterson KL, Vale W, Lee KF. ErbB2 is required for G protein-coupled receptor signaling in the heart. Proc Natl Acad Sci U S A. 2006;103(43):15889–93.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Goodyer MJ, Ismail JR, O’Reilly SP, Moylan EJ, Ryan CA, Hughes PA, et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J. 2009;2:9329.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol. 2008;26(9):1567–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Pirvulescu C, Mau C, Schultz H, Sperfeld A, Isbruch A, Renner-Lützkendorf H, et al. Breast Cancer during pregnancy: an interdisciplinary approach in our institution. Breast Care (Basel). 2012;7(4):311–4.CrossRefGoogle Scholar
  70. 70.
    El-Safadi S, Wuesten O, Muenstedt K. Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res. 2012;38(3):589–92.CrossRefPubMedGoogle Scholar
  71. 71.
    Mandrawa CL, Stewart J, Fabinyi GC, Walker SP. A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol. 2011;51(4):372–6.CrossRefPubMedGoogle Scholar
  72. 72.
    Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31(20):2532–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 2005;146(3):1301–11.CrossRefPubMedGoogle Scholar
  74. 74.
    Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta. 2004;25(6):560–72.CrossRefPubMedGoogle Scholar
  75. 75.
    Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev. 2009;6(8):465–77.Google Scholar
  76. 76.
    Berkane N. Gestational hypertensions: definitions and consequences in outcome of pregnancy. Ann Fr Anesth Reanim. 2010;29(3):e1–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Ishizuka S, Satou S. A case of delivery of healthy infant in breast cancer patient incidentally treated with goserelin acetate and tamoxifen during pregnancy. Breast Cancer. 2016;23(1):164–6.CrossRefPubMedGoogle Scholar
  78. 78.
    RCOG Green-top guideline No. 12. Pregnancy and breast cancer. UK royal college of obstetricians and Gynaecologists; 2011.Google Scholar
  79. 79.
    Bahrami A, Aledavood A, Anvari K, Hassanian SM, Maftouh M, Yaghobzade A, et al. The prognostic and therapeutic application of microRNAs in breast cancer: tissue and circulating microRNAs. J Cell Physiol. 2018;233(2):774–86.CrossRefPubMedGoogle Scholar
  80. 80.
    Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.CrossRefPubMedGoogle Scholar
  81. 81.
    Walter BA, Gómez-Macias G, Valera VA, Sobel M, Merino MJ. miR-21 expression in pregnancy-associated breast Cancer: a possible marker of poor prognosis. J Cancer. 2011;2:67–75.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Eedarapalli P, Jain S. Breast cancer in pregnancy. J Obstet Gynaecol. 2009;26(1):1–4.CrossRefGoogle Scholar
  83. 83.
    Ha JF, Longnecker N. Doctor-patient communication: a review. Ochsner J. 2010;10(1):38–43.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Perry S, Kowalski TL, Chang CH. Quality of life assessment in women with breast cancer, benefits, acceptability and utilization. Health Qual Life Outcomes. 2007;5:24.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol. 2005;23(15):3322–30.CrossRefPubMedGoogle Scholar
  86. 86.
    Rodsten JM Understanding the experience of pregnancy-associated breast Cancer - an interpretative phenomenological analysis. In: DCounsPsych, University of the West of England. 2017. http://eprints.uwe.ac.uk/30561. Accessed 26 Jul 2017.
  87. 87.
    Hayes SC, Hofmann SG. The third wave of CBT and the rise of process-based care. World Psychiatry. 2017;16(3):245–6.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    David D, Cristea I, Hofmann SG. Why cognitive behavioral therapy is the current gold standard of psychotherapy. Front Psychiatry. 2018;9:4.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cogn Ther Res. 2012;36(5):427–40.CrossRefGoogle Scholar
  90. 90.
    Hofmann SG, Asmundson GJ, Beck AT. The science of cognitive therapy. Behav Ther. 2013;44(2):199–212.CrossRefPubMedGoogle Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2018

Authors and Affiliations

  • Pavol Zubor
    • 1
    • 2
  • Peter Kubatka
    • 2
    • 3
  • Ivana Kapustova
    • 1
  • Lence Miloseva
    • 4
  • Zuzana Dankova
    • 2
  • Alexandra Gondova
    • 1
  • Tibor Bielik
    • 1
  • Stefan Krivus
    • 1
  • Jan Bujnak
    • 5
    • 6
  • Zuzana Laucekova
    • 1
  • Christina Kehrer
    • 7
    • 8
    • 9
  • Erik Kudela
    • 1
  • Jan Danko
    • 1
  1. 1.Department of Obstetrics and Gynaecology, Jessenius Faculty of MedicineComenius University in Bratislava, Martin University HospitalMartinSlovak Republic
  2. 2.Division of Oncology, Biomedical Center Martin, Jessenius Faculty of MedicineComenius University in BratislavaMartinSlovak Republic
  3. 3.Department of Medical Biology, Jessenius Faculty of MedicineComenius University in BratislavaMartinSlovakia
  4. 4.Department of Psychiatry and Clinical Psychology, Faculty of Medical ScienceGoce Delcev UniversityStipMacedonia
  5. 5.Department of Obstetrics and GynaecologyKukuras Michalovce HospitalMichalovceSlovakia
  6. 6.Oncogynecology UnitPenta Hospitals International, Svet ZdraviaMichalovceSlovakia
  7. 7.Centre for Obstetrics and GynaecologyRheinische Friedrich-Wilhelms-University of BonnBonnGermany
  8. 8.Breast Cancer Research CentreRheinische Friedrich-Wilhelms-University of BonnBonnGermany
  9. 9.Centre for Integrated Oncology, Cologne-BonnRheinische Friedrich-Wilhelms-University of BonnBonnGermany

Personalised recommendations